We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 13, 2021

Targeting BCL-2 With Venetoclax and Dexamethasone in Patients With Relapsed/Refractory T(11;14) Multiple Myeloma

American Journal of Hematology

 

Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Hematology
Targeting BCL-2 With Venetoclax and Dexamethasone in Patients With Relapsed/Refractory T(11;14) Multiple Myeloma
Am. J. Hematol 2020 Dec 28;[EPub Ahead of Print], JL Kaufman, C Gasparetto, FH Schjesvold, P Moreau, C Touzeau, T Facon, LH Boise, Y Jiang, X Yang, F Dunbar, D Vishwamitra, S Unger, RNT Macartney, J Pesko, Y Yu, AH Salem, JA Ross, WJ Hong, PC Maciag, JM Pauff, S Kumar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading